Deals channel feed

Roivant bumps stake in Im­muno­vant with a $200M deal. But with M&A off the ta­ble, shares crater

4 years ago

Ipsen con­tin­ues its shop­ping spree with a $1B-plus deal for Ex­i­cure's next-gen oligonu­cleotides

4 years ago

On the heels of Take­da pact, Pep­tiDream kicks off $2.2B deal to broad­en Al­ny­lam's siR­NA de­liv­ery scope

4 years ago

Eli Lil­ly teams up with KRAS drug pi­o­neer Yi Liu tar­get­ing small mol­e­cule I/O with $70M up­front

4 years ago

As­traZeneca castoff draws $123M wa­ger on CX­CR2 an­tag­o­nist as Are­na lines up a buy­out op­tion

4 years ago
Financing

Am­gen bel­lies back up to the M&A ta­ble for an­oth­er biotech buy­out, this time with a $2.5B deal for an an­ti­body play­er fo­cused on PS­MA

4 years ago

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

4 years ago
R&D

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's vac­cine

4 years ago
Financing

Take­da flesh­es out CNS pact with pep­tide drug­mak­er, set­ting aside $3.5B in fu­ture mile­stones

4 years ago
R&D

Bris­tol My­ers Squibb catch­es the SHP2 wave in a new col­lab­o­ra­tion deal with Bridge­Bio

4 years ago

Shelling out $5B+, PerkinElmer pays the big bucks for an­ti­body and reagent play­er

4 years ago
Outsourcing

Pfiz­er bets $1B cash on the orig­i­nal pro­tein de­graders as tech­nol­o­gy nears prime time

4 years ago

Af­ter chim­ing in an­ti­body to Covid-19 fight, Jun­shi drops $30M to kick off mR­NA joint ven­ture in Chi­na

4 years ago
China

The piv­ot: Turn­stone Bi­o­log­ics opens a new chap­ter with a switch to clin­i­cal de­vel­op­ment and a new ven­ture round to pay for it

4 years ago
Financing

PacBio en­gi­neers $800M buy­out of se­quenc­ing ri­val Om­niome as an­a­lysts fret over FTC ac­tion

4 years ago

Flex­ing its new­found wealth, BioN­Tech snaps up a TCR plat­form and man­u­fac­tur­ing site as Gilead ex­its

4 years ago
Cell/Gene Tx
Manufacturing

Celu­lar­i­ty emerges from SPAC merg­er dou­bled down on cell ther­a­pies as Bob Hariri down­grades ill-fat­ed Covid-19 pro­gram

4 years ago
Cell/Gene Tx

Ipsen bets up to $363M on an­oth­er shot at a de­bil­i­tat­ing con­di­tion re­lat­ed to Parkin­son's dis­ease

4 years ago

UK busi­ness sec­re­tary look­ing in­to Philip Mor­ris' pro­posed deal to ac­quire Vec­tura — re­port

4 years ago

EU set to launch full-scale in­ves­ti­ga­tion in­to Grail-Il­lu­mi­na deal amid an­titrust con­cerns — re­port

4 years ago
FDA+

As­traZeneca's planned takeover of Alex­ion clears last reg­u­la­to­ry re­view, deal to close next week

4 years ago

Eli Lil­ly swoops in to buy a small pro­tein drug de­vel­op­er and its glu­cose re­spon­sive in­sulin in $1B-plus deal

4 years ago

Scoop: Ac­tivist­s' at­tempt to take over in­fa­mous Mar­tin Shkre­li com­pa­ny fails, as ‘Phar­ma Bro’ votes from prison

4 years ago

Strug­gling Io­n­is li­cens­es Bi­cy­cle Ther­a­peu­tic­s' plat­form in a bid to de­vel­op drugs that can cross blood-brain bar­ri­er

4 years ago
First page Previous page 73747576777879 Next page Last page
A service from the Financial Times